{'fraction_non_alphanumeric': 0.02864816472694718, 'fraction_numerical': 0.011638316920322292, 'mean_word_length': 5.425287356321839, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
IL-6 induced enhanced clearance of proANP and ANP by insulin-degrading enzyme in T1DM mouse.

Cardiovascular disease (CVD) is the prevalent cause of morbidity and mortality in type I diabetes mellitus (T1DM) worldwide. However, the pathophysiological mechanisms underlying the relationship between CVD, CVD risk factors, and T1DM have not yet been sufficiently explored. Here we reported that insulin-degrading enzyme (IDE) effectively degrades the precursor of atrial natriuretic peptide (proANP) intracellular in HEK293T cells. Pro-inflammatory cytokine IL-6 elicited a significant dose-dependent increase in IDE protein expression. Inhibition of ERK/MAPK signaling pathway with selumetinib abolished IL-6-stimulated increase in IDE protein level and deceased in ANP secretion in H9C2 cells. Importantly, the T1DM mouse model displayed lower proANP in the heart and ANP in serum, due to increased IDE expression and activity. Our outcomes suggest a novel role of IL-6 on ANP metabolism via IDE and provide the possibilities for new potential therapeutic strategies for diabetes-related cardiovascular complications.